BP in Dialysis: Results of a Pilot Study

作者：Miskulin Dana C.; Gassman Jennifer; Schrader Ronald; Gul Ambreen; Jhamb Manisha; Ploth David W.; Negrea Lavinia; Kwong Raymond Y.; Levey Andrew S.; Singh Ajay K.; Harford Antonia; Paine Susan; Kendrick Cynthia; Rahman Mahboob; Zager Philip^*

来源：Journal of the American Society of Nephrology, 2018, 29(1): 307-316.

DOI：10.1681/ASN.2017020135

The optimal BP target for patients receiving hemodialysis is unknown. We randomized 126 hypertensive patients on hemodialysis to a standardized predialysis systolic BP of 110-140 mmHg (intensive arm) or 155-165 mmHg (standard arm). The primary objectives were to assess feasibility and safety and inform the design of a full-scale trial. A secondary objective was to assess changes in left ventricular mass. Median follow-up was 365 days. In the standardarm, the 2-week moving average systolic BP did not change significantly during the intervention period, but in the intensive arm, systolic BP decreased from 160 mmHg at baseline to 143 mmHg at 4.5 months. From months 4-12, the mean separation in systolic BP between arms was 12.9 mmHg. Four deaths occurred in the intensive arm and one death occurred in the standard arm. The incidence rate ratios for the intensive compared with the standard arm (95% confidence intervals) were 1.18 (0.40 to 3.33), 1.61 (0.87 to 2.97), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vascular access thrombosis, respectively. The intensive and standard arms had similar median changes (95% confidence intervals) in left ventricular mass of 20.84 (217.1 to 10.0) g and 1.4 (211.6 to 10.4) g, respectively. Although we identified a possible safety signal, the small size and short duration of the trial prevent definitive conclusions. Considering the high risk for major adverse cardiovascular events in patients receiving hemodialysis, a full-scale trial is needed to assess potential benefits of intensive hypertension control in this population.

• 出版日期2018-1